INTRODUCTION

Biological therapies have revolutionized the management of chronic inflammatory skin diseases, offering targeted approaches to modulate immune responses [1]. Conditions such as psoriasis, hidradenitis suppurativa (HS), pyoderma gangrenosum (PG), and severe atopic dermatitis (AD) often significantly impact the patient’s quality of life and may be refractory to conventional systemic treatments [2,3]. This article presents a single-center experience with biological agents in a cohort of 18 patients with diverse inflammatory dermatoses.

Patients and Methods

This retrospective study included 18 patients from Department C, KDV, who received biological therapy between December 2023 and May 2025. Ethical approval was waived due to the retrospective nature of the study. Patient demographics, treatment details, and outcomes are summarized in Table 1 and Table 2.

	Table 1: Patient treatment details.
	Table 2: Treatment outcomes and responses.

RESULTS

Among the 18 patients, the overall response to biological therapy was favorable, with significant clinical improvement observed across various conditions. The patient with pyoderma gangrenosum demonstrated a good clinical response to infliximab [4]. Both patients with hidradenitis suppurativa showed improvement in disease activity with their respective biological treatments [5]. The patient with atopic dermatitis experienced a reduction in disease severity with omalizumab [6]. Among the 15 psoriasis patients, the majority showed a good to excellent response to secukinumab [7,8]. The two psoriasis patients who switched from infliximab to secukinumab due to a poor initial response subsequently achieved a satisfactory clinical response [9,10]. No new or unexpected serious adverse events were reported during the observation period [11,12].

DISCUSSION

This study adds to the growing body of evidence supporting the effectiveness of biological therapies in complex inflammatory skin diseases [13]. Our cohort, although small, represents a diverse range of conditions and demonstrates the real-world applicability of these treatments in a clinical dermatology department. The successful switch from infliximab to secukinumab in two psoriasis patients underscores the individualized nature of biological therapy [14]. The observed favorable responses in pyoderma gangrenosum, hidradenitis suppurativa, and atopic dermatitis further support the broad utility of these targeted immunomodulators [15,16]. The limitations included the small sample size, retrospective design, and relatively short follow-up period [17].

CONCLUSION

Biological therapies, including infliximab, secukinumab, and omalizumab, are effective and generally well-tolerated treatments for severe inflammatory skin conditions in our patient cohort. The ability to switch therapies in non-responders provides valuable flexibility in managing these chronic diseases. Further large-scale studies are warranted to confirm these findings and explore long-term outcomes.

REFERENCES

1.Smith CH, Barker JN. Biologics in psoriasis:A new dawn?Lancet. 2000;356:1713-5.

2.Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277-94.

3.Green M, Feschuk A, Valdebran M. Hidradenitis suppurativa and diet:A cross-sectional analysis of reddit and review of the literature. Our Dermatol Online. 2024;15:312-3.

4.Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333:181-4.

5.Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2010;62:205-17.

6.Gyawalee M, Paudel V. Sociodemographic and clinical characteristics of chronic urticaria among patients attending the dermatology clinic in a tertiary-care hospital. Our Dermatol Online. 2023;14:240-8.

7.Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al;ERASURE Study Group;FIXTURE Study Group. Secukinumab in plaque psoriasis:Results of two phase 3 trials. N Engl J Med. 2014;371:326-38.

8.Yamamoto T. Radiological improvement of psoriatic arthritis by biologic therapy. Our Dermatol Online. 2021;12:82-3.

9.Reich K. The concept of treatment response and failure in psoriasis. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):13-22.

10.Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure:An efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. Br J Dermatol. 2024;190:836-45.

11.Akshay S, Harikishan YK. Cardiovascular comorbidities in patients with a severe form of psoriasis:A case-controlled study assessing clinical, biochemical, and radiological parameters. Our Dermatol Online. 2022;13:248-53.

12.Olivares-Guerrero M, Daudén E, Riera-Monroig J, González-Quesada A, Sahuquillo-Torralba A, Rivera-Díaz R, et al. Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry. J Eur Acad Dermatol Venereol. 2025;39:1643-55.

13.Puig L. Biologics in dermatology:Beyond psoriasis. Actas Dermosifiliogr. 2014;105:795-802.

14.Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis:Results from a multicentre experience. Br J Dermatol. 2019;180:1547-8.

15.Preetham P, Selvasudha, Kabilan N. Dermatoses induced by multikinase inhibitors:A case report. Our Dermatol Online. 2023;14:187-90.

16.López E, Cabrera R, Lecaros C. Targeted therapy for immune mediated skin diseases:What should a dermatologist know?An Bras Dermatol. 2024;99:546-67.

17.Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432-70.